Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

MLA

Boen, Monica, et al. “Thalidomide (Thal), Lenalidomide (Len), and Dexamethasone (Dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear.” Blood, vol. 112, no. 11, Nov. 2008, p. 2403. EBSCOhost, https://doi.org/10.1182/blood.V112.11.2403.2403.

APA

Boen, M., McKoy, J., West, D., Edwards, B., Mehta, J., Singhal, S., & Bennett, C. L. (2008). Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear. Blood, 112(11), 2403. https://doi.org/10.1182/blood.V112.11.2403.2403

Chicago

Boen, Monica, June McKoy, Dennis West, Beatrice Edwards, Jayesh Mehta, Seema Singhal, and Charles L. Bennett. 2008. “Thalidomide (Thal), Lenalidomide (Len), and Dexamethasone (Dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear.” Blood 112 (11): 2403. doi:10.1182/blood.V112.11.2403.2403.